InferMed Appoints New CEO.

Duane S. Lawrence Brings Extensive Experience in Global Sales and New Market Development

LONDON -- InferMed, a leading provider of advanced software solutions for clinical research and practice, has appointed Duane S. Lawrence as its Chief Executive Officer.

Mr Lawrence joins InferMed from MISYS Healthcare Systems International, where he held the role of General Manager from 2003. In this role he was responsible for all aspects of MISYS Healthcare operations outside North America, researching and opening new international markets across Europe as well as the Middle East and Asia.

Commenting on his appointment, Mr Lawrence said: "I am very pleased to be joining the InferMed team at this important time in their development. The company is uniquely positioned for dramatic growth in the healthcare and pharma space as our MACRO and Arezzo[R] solutions are significantly ahead of other competitive products. We are clearly positioned today to make important advances for our global client base, supporting clinical research and physicians in improving patient care."

Before becoming General Manager at MISYS, Duane initiated, developed and grew the Product Management and Account Management functions at MISYS Healthcare as well as holding the positions of Director, Client Implementation Services and Regional Sales Manager. Prior to this Duane held top sales roles in the US with B Braun Medical and Coca Cola USA, following his graduation from Notre Dame University with a B.B.A in Finance.

Roger Wallhouse, Chairman of InferMed, said: "This appointment marks a significant step in the development of InferMed. With his excellent track record in sales, and a proven ability to develop new markets, Duane will be hugely important in driving forward InferMed's sales of MACRO and Arezzo, and ensuring InferMed extends its position as a leading software provider."

About InferMed

InferMed Ltd is a provider of advanced software solutions for clinical research and practice. The Company was founded in 1999, as a spinout from the Imperial Cancer Research Fund's (now Cancer Research UK) Advanced Computational Laboratory, with the mission to commercialise highly advanced software technology developed for clinical research and practice. InferMed's products are currently used across healthcare, pharmaceutical and clinical research sectors worldwide

InferMed's lead products, MACRO and Arezzo were developed from work started at Cancer Research UK. MACRO supports clinical trials, helping with the collection of data and the management of trial protocols, and is currently being used for over 85,000 patients at more than 400 sites in 36 countries worldwide. Arezzo is highly advanced clinical decision support software designed to aid clinicians through the process of diagnosis and treatment. Arezzo provides active clinical guidelines and protocols at the point-of-care, reducing the risk of misdiagnosis and improving treatment for patients.

Website: www.infermed.com